title: Analysis of 454 sequencing error rate, error sources, and artifact recombination for detection of Low-frequency drug resistance mutations in HIV-1 DNA.
abstract: BACKGROUND
  454 sequencing technology is a promising approach for characterizing HIV-1 populations and for identifying low frequency mutations. The utility of 454 technology for determining allele frequencies and linkage associations in HIV infected individuals has not been extensively investigated. We evaluated the performance of 454 sequencing for characterizing HIV populations with defined allele frequencies.
  
  
  RESULTS
  We constructed two HIV-1 RT clones. Clone A was a wild type sequence. Clone B was identical to clone A except it contained 13 introduced drug resistant mutations. The clones were mixed at ratios ranging from 1% to 50% and were amplified by standard PCR conditions and by PCR conditions aimed at reducing PCR-based recombination. The products were sequenced using 454 pyrosequencing. Sequence analysis from standard PCR amplification revealed that 14% of all sequencing reads from a sample with a 50:50 mixture of wild type and mutant DNA were recombinants. The majority of the recombinants were the result of a single crossover event which can happen during PCR when the DNA polymerase terminates synthesis prematurely. The incompletely extended template then competes for primer sites in subsequent rounds of PCR. Although less often, a spectrum of other distinct crossover patterns was also detected. In addition, we observed point mutation errors ranging from 0.01% to 1.0% per base as well as indel (insertion and deletion) errors ranging from 0.02% to nearly 50%. The point errors (single nucleotide substitution errors) were mainly introduced during PCR while indels were the result of pyrosequencing. We then used new PCR conditions designed to reduce PCR-based recombination. Using these new conditions, the frequency of recombination was reduced 27-fold. The new conditions had no effect on point mutation errors. We found that 454 pyrosequencing was capable of identifying minority HIV-1 mutations at frequencies down to 0.1% at some nucleotide positions.
  
  
  CONCLUSIONS
  Standard PCR amplification results in a high frequency of PCR-introduced recombination precluding its use for linkage analysis of HIV populations using 454 pyrosequencing. We designed a new PCR protocol that resulted in a much lower recombination frequency and provided a powerful technique for linkage analysis and haplotype determination in HIV-1 populations. Our analyses of 454 sequencing results also demonstrated that at some specific HIV-1 drug resistant sites, mutations can reliably be detected at frequencies down to 0.1%.
authors: Advanced Biomedical Computing Center, SAIC Frederick, Frederick National Laboratory for Cancer Research, PO Box B, Frederick, MD, USA. shaow@mail.nih.gov
authors: Wei
authors: W
authors: Shao
authors: Valerie F
authors: VF
authors: Boltz
authors: Jonathan E
authors: JE
authors: Spindler
authors: Mary F
authors: MF
authors: Kearney
authors: Frank
authors: F
authors: Maldarelli
authors: John W
authors: JW
authors: Mellors
authors: Claudia
authors: C
authors: Stewart
authors: Natalia
authors: N
authors: Volfovsky
authors: Alexander
authors: A
authors: Levitsky
authors: Robert M
authors: RM
authors: Stephens
authors: John M
authors: JM
authors: Coffin
mesh_terms: D016477:Artifacts; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000821:virology; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods*; D008969:Molecular Sequence Data; D009154:Mutation; D016133:Polymerase Chain Reaction / Q000379:methods; D011995:Recombination, Genetic; D012107:Research Design; D017422:Sequence Analysis, DNA / Q000379:methods*
references: J Virol. 2008 Nov;82(21):10747-55
references: 18715933
references: Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20166-71
references: 22135472
references: Genome Res. 2007 Aug;17(8):1195-201
references: 17600086
references: Nucleic Acids Res. 2007;35(1):1-10
references: 16920744
references: AIDS. 2006 Mar 21;20(5):701-10
references: 16514300
references: PLoS Comput Biol. 2008 May 09;4(4):e1000074
references: 18437230
references: Nucleic Acids Res. 1990 Apr 11;18(7):1687-91
references: 2186361
references: Mol Biol Evol. 2010 Apr;27(4):819-32
references: 19955476
references: Nature. 2005 Sep 15;437(7057):376-80
references: 16056220
references: Proc Natl Acad Sci U S A. 2011 May 31;108(22):9202-7
references: 21576473
references: Nat Biotechnol. 2008 Oct;26(10):1117-24
references: 18846085
references: J Clin Microbiol. 2007 Mar;45(3):881-6
references: 17202274
references: J Infect Dis. 2009 Mar 1;199(5):693-701
references: 19210162
references: Biotechniques. 2011 Sep;51(3):167-77
references: 21906038
references: J Virol Methods. 2010 Oct;169(1):248-52
references: 20691210
references: Nucleic Acids Res. 1998 Apr 1;26(7):1819-25
references: 9512558
references: PLoS One. 2009 May 25;4(5):e5683
references: 19479085
references: J Clin Microbiol. 2001 Feb;39(2):464-73
references: 11158091
references: Genome Res. 2011 Mar;21(3):494-504
references: 21212162
references: J Virol. 2001 May;75(10):4832-42
references: 11312355
references: BMC Genomics. 2006 Oct 26;7:275
references: 17067373
references: Retrovirology. 2009 Feb 12;6:15
references: 19216757
references: AIDS. 2009 Nov 27;23(18):2541-3
references: 19907212
references: BMC Genomics. 2011 May 19;12:245
references: 21592414
references: BMC Bioinformatics. 2011 Jan 28;12:38
references: 21276213
references: Genome Biol. 2007;8(7):R143
references: 17659080
references: PLoS One. 2009 Jun 29;4(6):e6079
references: 19562031
references: PLoS One. 2010 Jul 07;5(7):e11345
references: 20628644
references: AIDS. 2008 Jul 31;22(12):1411-5
references: 18614863
references: PLoS One. 2011;6(7):e22741
references: 21799940
references: Pharmacogenomics. 2007 Oct;8(10):1437-41
references: 17979516
references: FEMS Microbiol Rev. 1997 Nov;21(3):213-29
references: 9451814